<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>ISoP / ASA Statistics and Pharmacometrics (SxP) Special Interest Group (SIG)</title>
    <link>/</link>
    <description>Recent content on ISoP / ASA Statistics and Pharmacometrics (SxP) Special Interest Group (SIG)</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 17 Feb 2021 00:00:00 +0000</lastBuildDate><atom:link href="/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>About</title>
      <link>/about/</link>
      <pubDate>Wed, 17 Feb 2021 00:00:00 +0000</pubDate>
      
      <guid>/about/</guid>
      <description>This is a mockup of a new ASA / ISOP Statistics and Pharmacometrics (SxP) Special Interest Group (SIG) website. The website is hosted under the ISOPlinks Github project and is built using the R {blogdown} package.
Please contact Stacey Tannenbaum or Mike K Smith for more information.</description>
    </item>
    
    <item>
      <title>MBMA subgroup webinar</title>
      <link>/2021/02/17/mbma-subgroup-webinar/</link>
      <pubDate>Wed, 17 Feb 2021 00:00:00 +0000</pubDate>
      
      <guid>/2021/02/17/mbma-subgroup-webinar/</guid>
      <description>The Model-Based Meta-Analysis sub-Special Interest Group (MBMA sub-SIG) of the Statistics and Pharmacometrics Special Interest group (SxP SIG) held an &amp;ldquo;Introduction to MBMA&amp;rdquo; webinar on January 16th 2021.
Abstract As landscapes for the treatment of many diseases have grown increasingly competitive and costs to conduct clinical trials have soared, it is critical to understand the landscape of available treatments, as well as the probability that a specific compound could compete successfully in this market.</description>
    </item>
    
  </channel>
</rss>
